Table 1. Clinical characteristics of 559 patients.
| Characteristics | Patient (n) | Percentage (%) |
|---|---|---|
| Sex | ||
| Female | 557 | 99.6 |
| Male | 2 | 0.4 |
| Age (years) | ||
| <50 | 291 | 52.1 |
| ≥50 | 268 | 47.9 |
| KPS | ||
| ≥70 | 340 | 60.8 |
| <70 | 219 | 39.2 |
| Stage of initial diagnosis | ||
| I | 28 | 5.0 |
| II | 195 | 34.9 |
| III | 208 | 37.2 |
| IV | 98 | 17.5 |
| Unknown | 30 | 5.4 |
| DFS (months) | ||
| <24 | 306 | 54.7 |
| ≥24 | 253 | 45.3 |
| Molecular type | ||
| HR+/HER2− | 160 | 28.6 |
| HER2+ | 296 | 53.0 |
| TNBC | 92 | 16.4 |
| Unknown | 11 | 2.0 |
| Number of extracranial metastatic organs | ||
| 0 | 24 | 4.3 |
| 1–2 | 220 | 39.4 |
| ≥3 | 315 | 56.3 |
| Site of extracranial metastasis | ||
| Soft tissues or lymph nodes | 384 | 68.7 |
| Bones | 312 | 55.8 |
| Livers | 267 | 47.8 |
| Lungs | 309 | 55.3 |
| Others | 201 | 36.0 |
| BM location | ||
| Parenchyma | 537 | 96.1 |
| Dura Mater | 35 | 6.3 |
| Pia Mater | 33 | 5.9 |
| Size of the largest BM (cm) | ||
| 0 (meningeal metastasis only) | 22 | 3.9 |
| <1 | 222 | 39.7 |
| 1–3 | 199 | 35.6 |
| >3 | 37 | 6.6 |
| Unknown | 79 | 14.1 |
| Number of BMs | ||
| 0 (meningeal metastasis only) | 22 | 3.9 |
| 1 | 166 | 29.7 |
| 2 | 51 | 9.1 |
| 3 | 22 | 3.9 |
| >3 | 235 | 42.0 |
| Unknown | 63 | 11.3 |
| With or without neurological symptoms onset BM | ||
| No | 341 | 61.0 |
| Yes | 218 | 39.0 |
| Preferred brain local treatment | ||
| Yes | 330 | 59.0 |
| No | 148 | 26.5 |
| Untreated | 64 | 11.4 |
| Unknown | 17 | 3.0 |
KPS, Karnofsky performance status; DFS, disease-free survival; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; BM, brain metastases.